Tonix Pharmaceuticals gains GPO coverage for TONMYA across 35m lives

Tonix Pharmaceuticals has secured a commercial payer coverage agreement through a leading group purchasing organisation (GPO), extending access to TONMYA (cyclobenzaprine HCl sublingual tablets) to approximately 35 million US commercial lives — around 20% of the estimated 177 million commercially insured patients in the country. The deal, effective 1 May 2026, represents the company's first managed care partnership since TONMYA's commercial launch in November 2025.

TONMYA received FDA approval on 15 August 2025 for the treatment of fibromyalgia in adults. The drug is positioned by Tonix as the first new prescription therapy approved in the indication for more than 15 years, with the company describing it as a first-in-class non-opioid analgesic. Its sublingual formulation is designed to bypass first-pass hepatic metabolism, reducing production of the long half-life metabolite norcyclobenzaprine that is associated with the oral tablet form of cyclobenzaprine — a muscle relaxant that has been used off-label in fibromyalgia for decades.

Payer landscape

Beyond commercial coverage, Tonix said TONMYA is already reimbursed under Medicaid in 38 states, covering roughly 55 million lives — approximately 73% of the US Medicaid population of around 75 million. Discussions with Medicare are continuing. The GPO agreement is structured with standard utilisation management criteria, meaning prior authorisation or step-therapy requirements will likely apply in many plans, a common hurdle for newer branded medicines entering crowded or historically generic-dominated categories.

Tonix chief executive Seth Lederman noted the company remains committed to pursuing additional coverage across commercial and government channels, and that a patient support programme — the TONMYA Together Support Program — is available to help eligible commercially insured patients manage out-of-pocket costs at local and digital pharmacies.

The company cited physician research indicating that 85% of first-line fibromyalgia treatments fail due to efficacy or tolerability issues, drawing on a 2024 primary research study commissioned by Tonix itself and a 2012 publication in Pain Medicine. Readers should note that the commissioned research was funded by the sponsor, which limits its independence as a source for efficacy comparisons.

Market context and competitive positioning

Fibromyalgia affects more than 10 million US adults, with women accounting for roughly 90% of patients. The approved treatment landscape has been sparse: the FDA approved duloxetine (Cymbalta) in 2004, pregabalin (Lyrica) in 2007, and milnacipran (Savella) in 2009 — all of which are now generic. No new branded therapy reached approval in the indication between 2009 and TONMYA's clearance in 2025, a gap that reflects both the clinical complexity of fibromyalgia and the regulatory difficulty of demonstrating efficacy in chronic pain conditions.

TONMYA's patent estate, which covers both its protective eutectic formulation and manufacturing technology, is expected to provide US market exclusivity until 2034–2035. That long runway is commercially significant, but payer access will be the more immediate determinant of uptake — particularly given the availability of low-cost generics and the entrenched prescribing habits built over two decades. Tonix is also investigating the compound in Phase 2 programmes for major depressive disorder and acute stress disorder, which, if successful, could broaden the commercial case and strengthen reimbursement negotiations.

The GPO agreement is a meaningful early signal for TONMYA's commercial trajectory, but coverage for 20% of commercial lives is a starting point rather than a ceiling. How quickly Tonix can extend contracts to additional payers, and on what utilisation management terms, will be closely watched by investors over the next two to four quarters.